Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2, Multicenter, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody-Drug Conjugate (ADC), in Combination With Atezolizumab With or Without Carboplatin as First-line Induction or Maintenance, in Subjects With Extensive-stage Small Cell Lung Cancer (ES-SCLC) (IDeate-Lung03)

NCT06362252 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT06362252
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06362252 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2, Multicenter, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody-Drug Conjugate (ADC), in Combination With Atezolizumab With or Without Carboplatin as First-line Induction or Maintenance, in Subjects With Extensive-stage Small Cell Lung Cancer (ES-SCLC) (IDeate-Lung03)
Lead sponsor
Daiichi Sankyo
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 22, 2024
Completion date
February 20, 2028
Enrollment
123 (estimated)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

extensive stage-small cell lung cancer